PMID- 17311504
OWN - NLM
STAT- MEDLINE
DCOM- 20070405
LR  - 20191210
IS  - 1434-6621 (Print)
IS  - 1434-6621 (Linking)
VI  - 45
IP  - 2
DP  - 2007
TI  - HER-2 protein concentrations in breast cancer cells increase before 
      immunohistochemical and fluorescence in situ hybridization analysis turn 
      positive.
PG  - 177-82
AB  - BACKGROUND: The level of HER-2/neu in breast cancer cells is normally measured by 
      immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). It 
      determines whether patients should be treated with trastuzumab (Herceptin). In 
      this study, HER-2 protein in breast cancer tissue was measured using a 
      quantitative method. METHODS: Tissue samples of malignant and adjacent benign 
      breast tissue were collected from 118 consecutive women admitted for surgical 
      treatment of breast cancer. The HER-2 protein concentration was determined by 2 
      HER-2 assays: ELISA and the Bayer ADVIA Centaur assay. Paraffin-embedded tissue 
      sections of the corresponding tumors were analyzed by IHC and FISH. RESULTS: 
      Increased HER-2 concentrations in cancer tissue were found compared to autologous 
      reference tissue (p<0.0001, Wilcoxon test) and normal breast tissue (p<0.0001, 
      Mann-Whitney test). Good concordance rates were observed between the methods: 
      95.8% for IHC and FISH; 86.4% for IHC and ELISA; and 87.3% for FISH and ELISA. 
      The HER-2 positivity rate was determined to 26.3% by ELISA, 12.7% by IHC and 
      16.9% by FISH. No correlation was found with tumor grade, axillary node status or 
      serum HER-2 levels. CONCLUSIONS: Detection of HER-2 overexpression by measuring 
      HER-2 in tissue extracts by ELISA seems to be more sensitive than IHC and FISH. 
      This suggests that some patients deprived of Herceptin treatment may benefit from 
      this treatment and may also explain the conversion phenomenon from HER-2-negative 
      to HER-2-positive observed in relapse and metastatic disease.
FAU - Olsen, Dorte A
AU  - Olsen DA
AD  - Department of Clinical Biochemistry, Vejle County Hospital, Vejle, Denmark. 
      doaaol@vgs.vejleamt.dk
FAU - Ostergaard, Birthe
AU  - Ostergaard B
FAU - Bokmand, Susanne
AU  - Bokmand S
FAU - Wamberg, Peter A
AU  - Wamberg PA
FAU - Jakobsen, Erik H
AU  - Jakobsen EH
FAU - Brandslund, Ivan
AU  - Brandslund I
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Breast Neoplasms/chemistry/drug therapy/*pathology
MH  - Cell Line, Tumor
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Molecular Diagnostic Techniques/*methods/standards
MH  - Neoplasm Proteins/analysis
MH  - Receptor, ErbB-2/*analysis
MH  - Sensitivity and Specificity
MH  - Trastuzumab
EDAT- 2007/02/22 09:00
MHDA- 2007/04/06 09:00
CRDT- 2007/02/22 09:00
PHST- 2007/02/22 09:00 [pubmed]
PHST- 2007/04/06 09:00 [medline]
PHST- 2007/02/22 09:00 [entrez]
AID - 10.1515/CCLM.2007.034 [doi]
PST - ppublish
SO  - Clin Chem Lab Med. 2007;45(2):177-82. doi: 10.1515/CCLM.2007.034.